By Kelly Davio Antibodies that deplete B cells, including rituximab, have demonstrated efficacy in the treatment of neurological conditions such as progressive multiple sclerosis (MS) and neuromyelitis optica spectrum…
Brain, awy010, https://doi.org/10.1093/brain/awy010 Published: 13 February 2018 Robert Wilson Mateusz Makuch Anne-Kathrin Kienzler James Varley Jennifer Taylor Mark Woodhall Jacqueline Palace M Isabel Leite Patrick…
BBA Clin. 2015 Jan 15;3:126-34. doi: 10.1016/j.bbacli.2015.01.003. eCollection 2015. Kariya Y1, Kariya Y1, Saito T1, Nishiyama S2, Honda T3, Tanaka K4, Yoshida M5, Fujihara K2,…
Mult Scler. 2015 Jul 24. pii: 1352458515591071. [Epub ahead of print] Source: Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse…
Research paper Sera from neuromyelitis optica patients disrupt the blood–brain barrier Fumitaka Shimizu1, Yasuteru Sano1, Toshiyuki Takahashi2, Hiroyo Haruki1, Kazuyuki Saito1, Michiaki Koga1, Takashi Kanda1 + Author Affiliations 1Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan 2Department of Neurology, Tohoku University Graduate School of Medicine, Miyagi, Japan Correspondence to Dr T Kanda, Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, 1-1-1, Minamikogushi, Ube, Yamaguchi 7558505, Japan; tkanda@yamaguchi-u.ac.jp Contributors FS and TK conceived and designed the study. All authors reviewed, amended and agreed on the final version of the manuscript.
Clinical Usefulness of Cell-based Indirect Immunofluorescence Assay for the Detection of Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder Eun-suk Kang, M.D.,1 Ju-Hong Min, M.D.,2 Kwang Ho Lee, M.D.,2 and Byoung Joon Kim, M.D.2 Author information ? Article notes ? Copyright and License information ? Go to: Abstract. Background The presence of antibodies to aquaporin-4 (AQP4) has been identified as a key characteristic of neuromyelitis optica spectrum disorder (NMOSD), an autoimmune inflammatory demyelinating central nervous system (CNS) disorder. We evaluated the performance of a cell-based indirect immunofluorescence assay (CIIFA) for detecting AQP4 antibodies using antigen prepared with a recombinant AQP4 peptide transfection technique and assessed the usefulness of CIIFA for diagnosis of NMOSD in routine clinical practice.
Aquaporin-4 Antibodies Are Not Related to HTLV-1 Associated Myelopathy.
J Neuroophthalmol. 2011 Dec 6
Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Tradtrantip L , Zhang H , Saadoun S , Phuan PW , Lam C , Papadopoulos MC , Bennett JL , Verkman AS . Source Departments of Medicine and Physiology, University of California, San Francisco, CA
OBJECTIVE: To investigate an association between serum B cell activating factor of TNF family (BAFF) levels and anti-aquaporin-4 (AQP4) antibody titers in patients with neuromyelitis optica (NMO) after rituximab treatment. BACKGROUND: Anti-AQP4 antibodies are present in approximately 70% of NMO patients. Such antibodies are probably pathogenic and the titers are elevated during relapse as compared with those in remission.
Neuromyelitis optica (NMO) is an inflammatory demyelinating disorder characterized by optic neuritis and acute myelitis. A parainfectious pathogenesis may play a partial role in the development of this disorder.
BACKGROUND: Antibodies to the water channel protein aquaporin-4 (AQP4), which is expressed in astrocytic endfeet at the blood brain barrier, have been identified in the serum of Neuromyelitis optica (NMO) patients and are believed to induce damage to astrocytes. However, AQP4 specific T helper cell responses that are required for the generation of anti-AQP4 antibodies and most likely also for the formation of intraparenchymal CNS lesions have not been characterized. METHODOLOGY/PRINCIPAL FINDINGS: Using overlapping 15-meric peptides of AQP4, we identified the immunogenic T cell epitopes of AQP4 that are restricted to murine major histocompatibility complex (MHC) I-A(b).